**[37] PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS: PRIMARY FOCUS ON IMMUNO-ONCOLOGY**

**Tsipi Keren-Lehrer1, 1 Compugen**

* **Investment Rational**   
  Cancer immunotherapy is the most promising field in cancer therapy today, following exciting results from anti-PD-1 antibodies. Compugen has discovered several novel immune checkpoint candidates with the potential to develop first-in-class biologics against them. This differentiates us from the many companies in this field pursuing known immune checkpoint targets and can potentially benefit unresponsive patient populations and indications.
* **Business Strategy**   
  The Company’s business model relies on maximizing the commercial value of its one-of-a kind systematic discovery capability by entering into various forms of revenue-sharing collaborations for its product candidates at both early and later stages of development. The company continues to advance CGEN-15029 as its highest priority internal mAb program towards clinical trials.
* **Core Technology**   
  Compugen discovers novel drug targets through a predictive, computational process that combines human biology derived from genome analysis with disease information derived from analysis of vast amounts of proprietary and public data. This process is generally applicable to many fields of medical interest and usually results in multiple drug target candidates, which are often difficult to identify using traditional approaches.
* **Product Profile/Pipeline**   
  Compugen has a broad early-stage discovery pipeline with multiple opportunities in areas of both high unmet need and high industry interest. In addition to advancing our collaboration with Bayer Healthcare we are working on several programs with exciting potential focused on therapeutic antibodies against selected target proteins both for cancer immunotherapy and antibody-drug conjugate cancer therapy.
* **What's Next?**   
  Compugen has expanded its development infrastructure and plans to advance its lead internal immuno-oncology program, CGEN-15029, toward IND-enabling activities and clinical testing. The company continues to advance its pipeline to value inflection points and in the future plans to selectively enter into revenue sharing agreements.